[1] Oxlade O,Murray M. Tuberculosis and poverty:why are the poor at greater risk in Indian[J].PLoS One,2012,7(11):e47533.[2] World Health Organization.Global tubereulosis control:surveillanee planning,finaneing.WHO Report 2009.WHO/HTM/TB/2009.411[C].Geneva:WHO,2009.[3] Mignone F,Codecasa LR,Scolfaro C,et al.The spread of drug-resistant tuberculosis in children:an Italian case series[J].Epidemiol Infect,2014,142(10):2049-2056.[4] Ferrer GC,da Silva RM,Ferrer KT,et al.The burden of disease due to tuberculosis in the state of Santa Catarina,Brazil[J].J Bras Pneumol,2014,40(1):61-68.[5] 李亚楠,何立新,朱建良,等.石家庄地区耐多药肺结核病患者耐药情况及相关因素分析[J].医学动物防制,2014,30(8):845-847.[6] 中国防痨协会.结核病诊断细菌学检验规程[J].中国防痨杂志,1996,18(1):30-33.[7] World Health Organization.Policy guidance on drug-susceptibility testing (DST) of second-line anti-tuberculosis drugs[C].Geneva WHO,2008.[8] 米热班·热夏提.371例肺结核患者耐药情况分析 [D].乌鲁木齐:新疆医科大学,2012.[9] 李燕芬,赵梅桂,刘振扬,等.初复治肺结核患者160例耐药情况临床分析[J].当代医学,2014,20(14):54-55.[10] 肖东楼,赵明刚,王宇.全国结核病防治规划实施工作指南(2008 版) [M].北京:中国协和医科大学出版社,2009.[11] Dara M,Dadu A,Kremer K,et al.Epidemiology of tuberculosis in WHO European Region and public health response[J].Eur Spine J,2013,22(Suppl 4):549-555.[12] Diel R,Vandeputte J,de Vries G,et al.Costs of tuberculosis disease in the European Union:a systematic analysis and cost calculation[J].Eur Respirat J,2014,43(2):554-565.[13] Makwakwa L,Sheu ML,Chiang CY,et al.Patient and heath system delays in the diagnosis and treatment of new and retreatment pulmonary tuberculosis cases in Malawi[J].BMC Infect Dis,2014,14:132.[14] 范常龙,王博,纪滨英.105例肺结核痰结核菌耐药情况分析[J].黑龙江医药,2014,27(4):850-851.[15] 车洋,于梅,许国章,等.332例复治肺结核患者一线抗结核药物耐药情况分析[J].中国卫生检验杂志,2014,24(23):3481-3483.[16] 翟广,李波,李玉芹,等.利福喷丁与利福平治疗肺结核疗效和安全性的Meta分析[J].吉林大学学报:医学版,2011,37(3):523-528.[17] 王黎霞,成诗明,陈明亭,等.2010年全国第五次结核病流行病学抽样调查报告[J].中国防痨杂志,2012,34(8):485-508.[18] 全国结核病流行病学抽样调查技术指导组.2000年全国结核病流行病学抽样调查报告[J].中国防痨杂志,2002,24(2):3-46.[19] 彭亦平,谭彩萍,史安良.81例耐药肺结核临床分析[J].临床肺科杂志,2012,17(1):84-85.[20] 高华强,陈奇峰,金法祥,等.绍兴市肺结核耐药情况分析[J].浙江预防医学,2014,26(3):242-244,262. |